


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/589,623
				Filing Date	August 16, 2006
				First Named Inventor	Lola WEISS et al
				Art Unit	1614
Examiner Name				Not Yet Assigned	
Attorney Docket Number				32361	
U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	US-4,371,720	01-1-1983	Johnson et al.	
	2	US-5,013,387	07-7-1991	Goodwin et al.	
	3	US-5,081,122	01-14-1992	Ward	
	4	US-5,292,736	08-8-1994	Kumar et al.	
	5	US-5,461,034	10-24-1995	Rodan et al.	
	6	US-5,618,955	08-8-1997	Mechoulam et al.	
	7	US-6,166,066	12-26-2000	Makriyannis et al.	
	8	US-6,403,123	06-11-2002	Scott et al.	
	9	US-6,410,588	06-25-2002	Feldmann et al.	
	10	US-6,531,636	03-11-2003	Mechoulam et al.	



FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Documents	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	11	PCT WO 00/19773	06-6-2000	Kochman et al.		
	12	PCT WO 98/41519	09-24-1998	Bender et al.		
	13	PCT WO 97/29079	08-14-1997	Inaba et al.		
	14	PCT WO 94/12466	09-9-1994	Mechoulam et al.		
	15	PCT WO 99/02499	01-21-1999	Inaba et al.		
	16	EP 0444451	04-4-1991	D'Ambra et al.		
	17	EP 0570920	11-24-1993	Mechoulam et al.		
	18	FR 2735774	09-12-1997	Rinaldi et al.		
Examiner Signature		/Jennifer Kim/		Date Considered	06/08/2010	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.
SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/589,623
				Filing Date	August 16, 2006
				First Named Inventor	Lola WEISS et al
				Group Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	2	Of	3	Attorney Docket Number	32361
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	19	Adams et al. "Isolation of Cannabinol, Cannabidiol and Quebrachitol From Red Oil of Minnesota Wild Hemp", Journal of the American Chemical Society, 62: 2194-2196, 1940.			
	20	Burstein et al. "Synthetic Nonpsychotropic Cannabinoids With Potent Antiinflammatory, Analgesic, and Leukocyte Antiadhesion Activities", Journal of Medicinal Chemistry, 35: 3135-3141, 1992.			
	21	Coffey et al. "Tetrahydrocannabinol Inhibition of Macrophage Nitric Oxide Production", Biochemical Pharmacology, 52: 743-751, 1996.			
	22	Devane et al. "Isolation and Structure of A Brain Constituent That Binds to the Cannabinoid Receptor", Science, 258: 1946-1949, 1992.			
	23	Edery et al. "Structural Requirements for Cannabinoid Activity", Annals of the NY Academy of Sciences, 191: 40-53, 1971.			
	24	Felder et al. "Anandamide, An Endogenous Cannabimimetic Eicosanoid, Binds to the Cloned Human Cannabinoid Receptor and Stimulates Receptor-Mediated Signal Transduction", Proc. Natl. Acad. Sci. USA, 90: 7656-7660, 1993.			
	25	Gaoni et al. "The Isolation and Structure of Δ ¹ -Tetrahydrocannabinol and Other Neutral Cannabinoids From Hashish", Journal of the American Chemical Society, 93: 217-224, 1971.			
	26	Hanuš et al. "Two New Unsaturated Fatty Acid Ethanolamides in Brain That Bind to the Cannabinoid Receptor", Journal of Medicinal Chemistry, 36: 3032-3034, 1993.			
	27	Hanuš et al. "2-Arachidonyl Glyceryl Ether, An Endogenous Agonsit of the Cannabinoid CB1 Receptor", Proc. Natl. Acad. Sci. USA, 98(7): 3662-3665, 2001.			
	28	Houry et al. "Benzoxocin and Benxoxonin Derivatives. Novel Groups of Terpenophenols With Central Nervous System Activity. A Correction", Journal of Medicinal Chemistry, 18(9): 951-952, 1975.			
	29	Zuardi et al. "Antipsychotic Effect of Cannabidiol", Journal of Clinical Psychiatry, 56(10): 485-486, 1995.			
	30	Formukong et al. "Analgesic and Antiinflammatory Activity of Constituents of Cannabis Sativa L.", Inflammation, 12(4): 361-371, 1988.			
	31	Venstrom et al. "Survival After Pancreas Transplantation in Patients With Diabetes and Preserved Kidney Function", JAMA, 290(21): 2817-2823, 2003. Correction: 291(13): 1566, 2004.			
	32	Kendall et al. "Pancreas and Islet Transplantation", The Endocrinologist, 5: 28-35, 1995.			
	33	Mechoulam "Marijuana: Chemistry, Pharmacology, Metabolism and Clinical Effects", Academic Press, 65: Book Info & Table of Contents, 1973.			
	34	Houry et al. "Benzoxocin and Benxoxonin Derivatives. Novel Groups of Terpenophenols With Central Nervous System Activity", Journal of Medicinal Chemistry, 17(3): 287-293, 1974.			

Signature	/Jennifer Kim/	Considered	06/08/2010
-----------	----------------	------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹. Applicant's unique citation designation number (optional). ². Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JK/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/589,623	
			Filing Date	August 16, 2006	
			First Named Inventor	Lola WEISS et al	
			Group Art Unit	1614	
			Examiner Name	Not Yet Assigned	
Sheet	3	Of	3	Attorney Docket Number	32361
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	35	Mechoulam et al. "Hashish - I. The Structure of Cannabidiol", Tetrahedron, 19: 2073-2078, 1963.			
	36	Mechoulam et al. "Identification of An Endogenous 2-Monoglyceride, Present in Canine Gut, That Binds to Cannabinoid Receptors", Biochemical Pharmacology, 50(1): 83-90, 1995.			
	37	Mechoulam et al. "Recent Advances in the Chemistry and Biochemistry of Cannabis", Chemical Reviews, 76(1): 75-112, 1976.			
	38	Mechoulam et al. "Synthesis and Biological Activity of Five Tetrahydrocannabinol Metabolites", Journal of the American Chemical Society, 94(22): 7930-7931, 1972.			
	39	Mechoulam et al. "Stereochemical Requirements for Cannabinoid Activity", Journal of Medicinal Chemistry, 23(10): 1068-1072, 1980;			
	40	Mechoulam et al. "Chemical Basis of Hashish Activity", Science, 169(3945): 611-612, 1970.			
	41	Mechoulam et al. "Synthesis of the Individual, Pharmacologically Distinct, Enantiomers of A Tetrahydrocannabinol Derivative", Tetrahedron: Asymmetry, 1(5): 315-318, 1990.			
	42	Murphy et al. "Cannabinoid Geometry and Biological Activity", Marijuana/Cannabinoids: Neurobiology and Neurophysiology, P.1-33, 1992.			
	43	Leite et al. "Anticonvulsant Effects of the (-) and (+) Isomers of Cannabidiol and Their Dimethylheptyl Homologs", Pharmacology, 24: 141-146, 1982.			
	44	Zuardi et al. "Effects of Cannabidiol in Animal Models Predictive of Antipsychotic Activity", Psychopharmacology, 104(2): 260-264, 1991.			
	45	Rhee et al. "Cannabinol Derivatives: Binding to Cannabinoid Receptors and Inhibition of Adenylylcyclase", Journal of Medicinal Chemistry, 40: 3228-3233, 1997.			
	46	Robertson "Seminars in Medicine of the Beth Israel Hospital, Boston: Pancreatic and Islet Transplantation for Diabetes - Cures of Curiosities?", The New England Journal of Medicine, 327(26): 1861-1868,			
	47	Petrzilkka et al. "Synthese und Chiralität des (-)-Cannabidiols", Helvetica Chimica Acta, 50, Fasciculus 2(73-74/Chap.74): 719-723, 1967.			
	48	Sheskin et al. "Structural Requirements for Binding of Anandamide-Type Compounds to the Brain Cannabinoid Receptor", Journal of Medicinal Chemistry, 40: 659-667, 1997.			
	49	Srebnik et al. "Base-Catalysed Double-Bond Isomerizations of Cannabinoids: Structural and Stereochemical Aspects", Journal of the Chemical Society, Perkin Transactions I, P.2881-2886, 1984.			

Signature	/Jennifer Kim/	Considered	06/08/2010
-----------	----------------	------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹. Applicant's unique citation designation number (optional). ². Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JK/

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JK/